Wells Fargo analyst Derek Archila lowered the firm’s price target on Blueprint Medicines to $107 from $115 and keeps an Overweight rating on the shares. The firm thinks the guidance for fiscal 2024 seems conservative and believes Blueprint is set up for a beat and raise year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines provides 2024 financial guidance
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines price target raised to $70 from $58 at Barclays
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
